Aevi Genomic Medicine, Inc. reported consolidated earnings results for the fourth quarter and year ended December 31, 2017. For the quarter, the company reported net loss of $7.16 million or $0.13 per share against $8.48 million or $0.23 per share a year ago. For the year, the company reported operating loss of $34,700,000 against $41,879,000 a year ago. Loss before taxes on income was $34,714,000 against $41,888,000 a year ago. Net loss was $34,714,000 or $0.83 per basic and diluted share against $41,904,000 or $1.19 per basic and diluted share a year ago.